1. Home
  2. HURN vs TLX Comparison

HURN vs TLX Comparison

Compare HURN & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huron Consulting Group Inc.

HURN

Huron Consulting Group Inc.

N/A

Current Price

$124.94

Market Cap

2.2B

ML Signal

N/A

Logo Telix Pharmaceuticals Limited American Depositary Shares

TLX

Telix Pharmaceuticals Limited American Depositary Shares

N/A

Current Price

$8.77

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HURN
TLX
Founded
2002
2015
Country
United States
Australia
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.2B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
HURN
TLX
Price
$124.94
$8.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$215.50
$21.13
AVG Volume (30 Days)
292.4K
300.1K
Earning Date
04-28-2026
04-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
5.84
N/A
Revenue
$1,699,143,000.00
N/A
Revenue This Year
$11.74
N/A
Revenue Next Year
$10.55
N/A
P/E Ratio
$22.27
$150.33
Revenue Growth
11.65
N/A
52 Week Low
$116.12
$6.28
52 Week High
$186.78
$19.93

Technical Indicators

Market Signals
Indicator
HURN
TLX
Relative Strength Index (RSI) 34.33 64.04
Support Level $118.18 $7.72
Resistance Level $138.06 $9.92
Average True Range (ATR) 4.92 0.26
MACD 0.09 0.15
Stochastic Oscillator 1.08 81.14

Price Performance

Historical Comparison
HURN
TLX

About HURN Huron Consulting Group Inc.

Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.

About TLX Telix Pharmaceuticals Limited American Depositary Shares

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Share on Social Networks: